Regen BioPharma Inc

RGBPdata completeness 75%13 fiscal years on file

Data notes: no data for concept 'capex'

i. The business — what you’d actually own

Figure	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenue	$61,194¹	$125,517²	$236,560³	$236,560⁴	$236,561⁴
Net income	−$6.77M⁵	$2.44M⁶	$1.16M⁷	−$668,255⁸	−$1.27M⁸
Operating cash flow	−$1.13M⁹	−$606,921¹⁰	−$173,917¹¹	−$751,536¹²	−$383,591¹²
Capital expenditure	—	—	—	—	—
Free cash flow (derived)	—	—	—	—	—
Total debt	—	—	—	—	—
Cash & equivalents	$727,162¹³	$51,204¹³	$121,037¹⁴	$716¹⁵	$69,555¹⁵
Diluted shares	3.01B	3.1M	3.5M	4.1M	23.5M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$2.67

your share of equity

Profit it earned you last year

−$0.54

Free cash flow it threw off

—

Debt you’d be carrying

—

10 shares is a claim on −$2.67 of net worth that earned you −$0.54 last year.

iii. Is this a good business?

Moat signal · return on equity

— avg · 5y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

−99% shares · 5y

Share count is down 99% over 5 years — management has been buying back stock, quietly handing owners a bigger slice.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 0 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts